INTELLIA THERAPEUTICS

Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

30 Nov 2022 21:28:58 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces Proposed Public Offering of Common Stock

30 Nov 2022 16:36:59 By Nasdaq GlobeNewswire

Intellia Therapeutics Presents New Interim Data from First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma & Immunology 2022 Annual Scientific Meeting

12 Nov 2022 16:30:00 By Nasdaq GlobeNewswire

Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis at the American Heart Association Scientific Sessions 2022

05 Nov 2022 16:00:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress

03 Nov 2022 07:30:01 By Nasdaq GlobeNewswire

Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 ACAAI Annual Scientific Meeting

31 Oct 2022 07:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2022 Earnings and Company Updates

27 Oct 2022 07:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics to Present at October Healthcare Investor Conferences

26 Sep 2022 07:30:00 By Nasdaq GlobeNewswire

Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis

16 Sep 2022 07:15:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)

16 Sep 2022 07:00:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces Upcoming Investor Event to Present Interim Clinical Data from Ongoing First-in-Human Studies of NTLA-2002 and NTLA-2001 on September 16, 2022

08 Sep 2022 16:01:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2002, an Investigational CRISPR Therapy for the Treatment of Hereditary Angioedema

01 Sep 2022 16:01:00 By Nasdaq GlobeNewswire

Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 Bradykinin Symposium

23 Aug 2022 09:59:42 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress

04 Aug 2022 07:30:01 By Nasdaq GlobeNewswire

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2022 Earnings and Company Updates

27 Jul 2022 07:30:00 By Nasdaq GlobeNewswire

Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose

24 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress™ 2022

08 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress

05 May 2022 07:30:01 By Nasdaq GlobeNewswire

Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of Directors

02 May 2022 16:01:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its CRISPR-Engineered Allogeneic Platform at the 2022 Keystone Symposia’s Precision Genome Engineering Conference

02 May 2022 07:30:00 By Nasdaq GlobeNewswire